Evidence map›Paper›PMID 29401462›Full record

ArticlePloS one2018

Synthesis, stabilization, and characterization of the MR1 ligand precursor 5-amino-6-D-ribitylaminouracil (5-A-RU).

Kelin Li, Charles K Vorkas, Ashutosh Chaudhry, Donielle L Bell, Richard A Willis, Alexander Rudensky, John D Altman, Michael S Glickman, Jeffrey Aubé

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. MAIT Cells Modulate Innate Immune Cells and Inhibit Colon Cancer Growth.bioRxiv : the preprint server for biology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Kelin LiDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Charles K VorkasDivision of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
Ashutosh ChaudhryImmunology Program, Sloan Kettering Institute, New York, New York, United States of America.
Donielle L BellDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Richard A WillisDivision of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
Alexander RudenskyImmunology Program, Sloan Kettering Institute, New York, New York, United States of America.
John D AltmanDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Michael S GlickmanDivision of Infectious Diseases, Weill Cornell Medicine, New York, New York, United States of America.
Jeffrey AubéDivision of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America.ORCID 0000-0003-1049-5767
Emory University · USKettering University · USMemorial Sloan Kettering Cancer Center · USUniversity of North Carolina at Chapel Hill · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Viable but Nonculturable MtbU19AI111143 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI GLICKMAN, MICHAEL S, NATHAN, CARL FRANCIS · 2014 to 2020
$48.6M
Role of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 2014 to 2020
$20.1M
T32: Pathogenesis of Infectious Diseases Training ProgramT32AI007613 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 1999 to 2026
$8.8M
NCI NIH HHS P30 CA008748NIAID NIH HHS HHSN272201300006CNIAID NIH HHS T32 AI007613NIAID NIH HHS U19 AI111143NIAID NIH HHS U19 AI111211NIH HHS P30 CA008748NIH HHS P51 OD011132NIH HHS U19 AI111211NIH HHS U19 AI11143
6 · The paper itself

Abstract

Mucosal-associated invariant T (MAIT) cells are an abundant class of innate T cells restricted by the MHC I-related molecule MR1. MAIT cells can recognize bacterially-derived metabolic intermediates from the riboflavin pathway presented by MR1 and are postulated to play a role in innate antibacterial immunity through production of cytokines and direct bacterial killing. MR1 tetramers, typically stabilized by the adduct of 5-amino-6-D-ribitylaminouracil (5-A-RU) and methylglyoxal (MeG), are important tools for the study of MAIT cells. A long-standing problem with 5-A-RU is that it is unstable upon storage. Herein we report an efficient synthetic approach to the HCl salt of this ligand, which has improved stability during storage. We also show that synthetic 5-A-RU•HCl produced by this method may be used in protocols for the stimulation of human MAIT cells and production of both human and mouse MR1 tetramers for MAIT cell identification.

Indexed as

Histocompatibility Antigens Class IHumansImmunity, InnateLigandsMinor Histocompatibility AntigensMucosal-Associated Invariant T CellsRibitolUracil5-amino-6-D-ribitylaminouracilHistocompatibility Antigens Class ILigandsMinor Histocompatibility AntigensMR1 protein, humanRibitolUracil

Identifiers

PMID29401462
PMCPMC5798775
OpenAlexW2793748604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.